Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Mabwell leads development of new generation nectin-4 ADCs in China for triple-negative breast cancer, says GlobalData

Mabwell (Shanghai) Bioscience recently received the National Medical Products Administration (NMPA) approval for its 9MW2821, a novel nectin-4 targeting ADC (antibody-drug conjugate), to enter Phase II clinical trial in China. The preliminary clinical results of the Phase I/II study presented at the 2024 American Society of Clinical Oncology (ASCO) annual meeting demonstrated promising efficacy in […]
Read more

SC0062 trial results highlight BioCity’s potential to differentiate in kidney disease space, says GlobalData

BioCity Biopharma recently announced positive results from the ongoing 2-SUCCEED trial. The use of SC0062 resulted in a clinically meaningful and statistically significant reduction in proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN). The aging global population will lead to an increase in the prevalence of chronic kidney disease (CKD), leading to an expansion […]
Read more

Majority of UK physicians see continued rise in telemedicine usage, reveals GlobalData

The COVID-19 pandemic has significantly accelerated telemedicine adoption globally, with 76% of UK physicians* reporting increased usage post-pandemic. An overwhelming 89% of physicians expect further growth in telemedicine use, indicating strong confidence in the future expansion and integration of telemedicine into routine healthcare practices, according to GlobalData, a leading data and analytics company. GlobalData’s latest […]
Read more

AbbVie’s Humira loss of exclusivity a missed opportunity for competitors, says GlobalData

AbbVie‘s market leadership, driven by its flagship disease-modifying antirheumatic drug Humira (adalimumab), faced a significant test with the 2023 loss of patent protection. Despite an anticipated competitive surge, rivals have struggled to capitalize. AbbVie’s strategic shift to Skyrizi (risankizumab) and Rinvoq (upadacitinib) has solidified its position, underscoring a missed opportunity for competitors in the immunology […]
Read more

Diagnosed prevalent cases of chronic kidney disease to reach 22.97 million across 7MM in 2033, predicts GlobalData

The diagnosed prevalent cases of chronic kidney disease (CKD) across the seven major markets (*7MM) are projected to increase at an annual growth rate (AGR) of 0.90% from 21.08 million in 2023 to 22.97 million in 2033, forecasts GlobalData, a leading data and analytics company. GlobalData’s latest report, “Chronic Kidney Disease: Epidemiology Forecast to 2033,” […]
Read more

Synergistic safety profile could increase sublingual apomorphine competitiveness, says GlobalData

Sublingual apomorphine (SL-APO) is a dopamine agonist (DA) marketed by Bial under the brand name Kynmobi in several countries for the on-demand treatment of levodopa wear-off (OFF-episodes) that are not sufficiently controlled by levodopa “add-on” (adjunct) therapies. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Diego Santos García presented a […]
Read more

Opicapone demonstrates efficacy in real-world clinical practice, says GlobalData

Opicapone is a catechol-O-methyltransferase (COMT) inhibitor marketed in several countries by either Amneal Pharmaceuticals or Bial, depending on region, under the brand name “Ongentys” for the treatment of levodopa wear-off in Parkinson’s disease (PD). At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Maria-Rosario Luquin and Dr. Lydia López Manzanares separately […]
Read more

Safinamide outperforms rasagiline in efficacy, cost-efficacy, and forecasted sales, says GlobalData

Safinamide is a monoamine oxidase B (MAO-B) inhibitor marketed in several countries under the brand name Xadago by Newron Pharmaceuticals for the treatment of levodopa wear-off in Parkinson’s disease (PD). At the 10th Congress of the European Academy of Neurology (EAN) 2024, Dr. Ester Morales García presented a pharmacoeconomic report comparing safinamide to its competitor […]
Read more

Prioritized investments from pharma companies shaping competitive pipeline landscape of bronchiectasis, says GlobalData

Recent studies have allowed the unexplored field of bronchiectasis to be further investigated by shedding light on the mechanisms behind the disease’s pathophysiology. In recent years, bronchiectasis has garnered a significant amount of attention, with pharmaceutical companies prioritizing their investments in the development of promising pipeline agents to treat the disease through various mechanisms of […]
Read more

Healey platform data to pave phase III path for Prilenia’s pridopidine, says GlobalData

Developing disease-modifying treatments for amyotrophic lateral sclerosis (ALS), a rare and aggressive disease, has proven challenging. The high failure rate in ALS clinical trials is often attributed to the disease’s unclear etiology and complex pathophysiology. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Prilenia Therapeutics presented promising results from the additional […]
Read more

Ajovy benefits diminish with migraine treatment cessation and re-initiation, says GlobalData

The interim results from the observational, prospective Phase IV Pan-European Real-Life (PEARL) study, presented at the 10th Congress of the European Academy of Neurology, indicate that treatment cessation and re-initiation can reduce the benefits of Teva Pharmaceutical’s Ajovy for migraine management. Continuous administration of Ajovy is crucial for effective prevention, challenging current guidelines that recommend […]
Read more

Preventative treatment of chronic migraine will continue to evolve in short-term with anti-CGRP mAbs effectiveness, says GlobalData

OnabotulinumtoxinA (BoNT-A) and monoclonal antibodies against the calcitonin gene-related protein (anti-CGRP mAbs) have emerged as the first disease-specific preventative treatments to be approved for chronic migraine. At the 10th Congress of the European Academy of Neurology (EAN) 2024, Danilo Antonio Montisano, MD, presented real-world evidence findings from a retrospective, observational multicenter cohort study (RAMO) comparing […]
Read more

VNS and cenobamate combo therapy success paves way for cenobamate monotherapy, says GlobalData

At the recently held 10th Congress of the European Academy of Neurology (EAN), two investigator-led ePresentation sessions on epilepsy outlined the effectiveness of a combination of a new anti-seizure medication (ASM), Xcopri (cenobamate) and vagus nerve stimulation (VNS) in managing drug-resistant epilepsy (DRE). The combination therapy demonstrated significant improvements in seizure control, highlighting its potential […]
Read more
1 … 16 17 18 19 20 … 108